For locally advanced cervical cancer, there are two main treatment options:
One is radical chemoradiotherapy (a combination of radiotherapy and chemotherapy aimed at curing the disease).
The other is having neoadjuvant treatment first (treatment given before the main surgery to shrink the tumor) followed by radical surgery.
So far, there's no clear answer on which of these two options is better. In general, cervical cancer responds well to immunotherapy. But we still don't know for sure if adding immunotherapy to neoadjuvant chemotherapy can improve the treatment effect for locally advanced cervical cancer, or even make it better than radical chemoradiotherapy.
This study aims to compare the effects of two approaches: radical chemoradiotherapy versus neoadjuvant chemotherapy plus immunotherapy followed by surgery.
Aged ≥ 18 years and ≤ 70 years;
Cervical cancer with pathological types being squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma;
Staged IB3 or IIA2 according to the FIGO 2018 staging system, as assessed by the investigator;
ECOG performance status of 0-2, or KPS score ≥ 70;
Participated in other clinical trials within 30 days before receiving the first dose of chemotherapy drugs or during the treatment period.
Previously received any other anti-tumor treatment for cervical cancer.
Non-HPV-related cervical cancer.
Needing to receive other anti-tumor treatments during the study treatment period.